2024
Nutraceuticals Unveiled a Multifaceted Neuroprotective Mechanisms for Parkinson’s Disease: Elixir for the Brain
Soni D, Jamwal S, Chawla R, Singh S, Singh D, Singh T, Khurana N, Kanwal A, Dureja H, Patil U, Singh R, Kumar P. Nutraceuticals Unveiled a Multifaceted Neuroprotective Mechanisms for Parkinson’s Disease: Elixir for the Brain. Food Reviews International 2024, 40: 3079-3102. DOI: 10.1080/87559129.2024.2337766.Peer-Reviewed Original ResearchPre-clinicalGut-brain axisProtein ubiquitinationParkinson's diseaseMitochondrial dysfunctionSignaling pathwayMolecular mechanismsRelieve PD symptomsSymptoms of PDClinical trialsHealth benefits of nutraceuticalsBenefits of nutraceuticalsCustomized therapyClinical aspectsExpression of PDMediterranean dietNeurotransmitter imbalanceNeuroprotective mechanismsNeuroprotective potentialOxidative stressDiseasePD symptomsHealth benefitsSymptomsUbiquitin
2021
Pioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders
Blackburn JK, Jamwal S, Wang W, Elsworth JD. Pioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders. Neurochemistry International 2021, 152: 105222. PMID: 34767873, PMCID: PMC8712400, DOI: 10.1016/j.neuint.2021.105222.Peer-Reviewed Original ResearchConceptsPON2 expressionParkinson's diseaseParaoxonase 2Male African green monkeysShort-term animal modelsOxidative stressPeroxisome proliferator-activated receptor gammaEffect of pioglitazoneWeeks of treatmentProliferator-activated receptor gammaNonhuman primate brainParaoxonase-2 expressionRegion-dependent expressionSex-specific therapeuticsAnti-diabetic drug pioglitazoneAfrican green monkeysDorsolateral prefrontal cortexOral pioglitazonePreclinical evidenceSubstantia nigraClinical trialsPON2 mRNAAnimal modelsPioglitazonePrimate brain
2020
PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders
Jamwal S, Blackburn J, Elsworth JD. PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacology & Therapeutics 2020, 219: 107705. PMID: 33039420, PMCID: PMC7887032, DOI: 10.1016/j.pharmthera.2020.107705.Peer-Reviewed Original ResearchConceptsNeurodegenerative disordersParkinson's diseaseAlzheimer's diseaseParaoxonase 2Mitochondrial biogenesisNeurodegenerative diseasesHuntington's diseasePeroxisome proliferator-activated receptorProliferator-activated receptorPotential therapeutic targetDevastating neurological disorderFunction of neuronsPeroxisome proliferator-activated receptor gamma co-activator-1 alphaPharmacological-based therapiesSymptomatic treatmentCurrent therapiesClinical trialsLigand-inducible transcription factorsTherapeutic targetNeurological disordersDiseasePPARγ modulatorsProgressive lossMitochondrial dysfunctionPromising targetGene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives
Jamwal S, Elsworth JD, Rahi V, Kumar P. Gene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives. Expert Review Of Neurotherapeutics 2020, 20: 1123-1141. PMID: 32720531, DOI: 10.1080/14737175.2020.1801424.Peer-Reviewed Original ResearchConceptsGene therapyClinical trialsDisease-modifying therapiesMutant huntingtinTreatment of HDAntibody-based therapiesPotential therapeutic interventionsNew therapeutic targetsGene-based therapiesImmune activationClinical dataImmunotherapyTherapeutic targetFunctional restorationTherapeutic interventionsTherapyHD pathogenesisMHTT proteinRecent updatesFuture perspectivesPromising strategyTrialsCurrent statusConsiderable attentionHDAn updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic
Jamwal S, Gautam A, Elsworth J, Kumar M, Chawla R, Kumar P. An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic. Life Sciences 2020, 257: 118105. PMID: 32687917, PMCID: PMC7366108, DOI: 10.1016/j.lfs.2020.118105.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsSARS-CoV-2Secondary complicationsPathogenic SARS-CoV-2Hospitalized COVID-19 patientsRecovered COVID-19 patientsCOVID-19Brief clinical updatesNew SARS-CoV-2 virusCOVID-19 pathogenesisACE-2Broad-spectrum antiviral drugsCOVID-19 infectionCoronavirus disease 2019Vaccines/drugsSARS-CoV-2 virusHepatic complicationsViral burdenConvalescent plasmaClinical updateAngiotensin IIImmune damageEpidemiological featuresClinical trialsDisease 2019
2016
Tetrabenazine: Spotlight on Drug Review
Kaur N, Kumar P, Jamwal S, Deshmukh R, Gauttam V. Tetrabenazine: Spotlight on Drug Review. Annals Of Neurosciences 2016, 23: 176-185. PMID: 27721587, PMCID: PMC5043267, DOI: 10.1159/000449184.Peer-Reviewed Original ResearchTreatment of choreaHyperkinetic disorderOnly US FoodVesicular monoamine transporter 2Further clinical trialsMonoamine transporter 2Treatment of psychosisMechanism of actionClinical efficacyTardive dyskinesiaClinical trialsClinical studiesMonoamine storesTourette syndromeDrug AdministrationUS FoodHuntington's choreaChoreaTherapeutic potentialTetrabenazineTransporter 2Huntington's diseaseAdverse effectsLack of awarenessDisease